SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality—a secondary analysis of the ACTIV-1 trial
N protein levels could provide insights into COVID-19 disease progression and prognosis. Further research is needed to explore the clinical implications of these findings to optimize patient care and enhance outcomes.
Authors
- Luis Parra-Rodriguez (ORCID: https://orcid.org/0000-0003-1746-0743)
- Christopher Palma (ORCID: https://orcid.org/0000-0002-1758-1687)
- Kimberly Enders
- William G. Powderly (ORCID: https://orcid.org/0000-0001-7808-3086)
- Alfredo J Mena Lora (ORCID: https://orcid.org/0000-0002-8337-757X)
- Kevin J. Anstrom (ORCID: https://orcid.org/0000-0001-6452-2172)
- Kevin J. Saliba (ORCID: https://orcid.org/0000-0003-3345-8440)
- Huimin Wu (ORCID: https://orcid.org/0000-0001-7023-8362)
- P. Brian Smith
- Samuel A. Bozzette
- Sylvain Laverdurre
Institutions
- University of North Carolina at Chapel Hill (US)
- Leidos (United States) (US)
- Duke University (US)
- Washington University in St. Louis (US)
- University of Illinois Chicago (US)
- Clinical Research Institute (US)
- National Institute of Allergy and Infectious Diseases (US)
- National Center for Advancing Translational Sciences (US)
- Leidos Biomedical Research Inc. (United States)
- University of Oklahoma Health Sciences Center (US)
- University of Rochester (US)
Publication Details
- Journal
- Therapeutic Advances in Infectious Disease
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1177/20499361251333617
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biomedical Advanced Research and Development Authority
- National Institute of Allergy and Infectious Diseases
- National Center for Advancing Translational Sciences